FDA LABEL RECORD
SAJAZIR
ICATIBANT. FDA prescribing information for this product, as published on the retrieval date below.
AS THE LABEL RECORDS IT
Product details
| Brand name | SAJAZIR |
|---|---|
| Generic name | ICATIBANT |
| Labeller | Cycle Pharmaceuticals Ltd-Uk |
| Route | SUBCUTANEOUS |
| Label version | 5 |
| Effective | 2024-02-16 |
| Retrieved by this site | 2026-10-03 |
| Full label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1756aca0-21a1-4898-8d6c-9666738db45c |
INDICATIONS AND USAGE
Quoted from the FDA label
1 INDICATIONS AND USAGE SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. SAJAZIR (icatibant) injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )
What this page is
A reproduction of a public FDA label record. Everything quoted above is the labeller's wording as published by the FDA, not this site's. Nothing here is regulatory, legal or medical advice, and a label being reproduced says nothing about whether a product is available in any particular country. Labels are revised often; the retrieval date above says when this copy was taken, and the full current label is at the link.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.